Two New Clinical Sites Join the MELISSA Clinical Study

The MELISSA clinical study has added two new clinical sites: one in the Netherlands, Radboud University Medical Center, and one in Denmark, Steno Diabetes Center Copenhagen.

The study is testing the innovative MELISSA app, which provides people living with diabetes with daily, personalised advice on insulin dosing and diabetes management. By bringing together diabetes data and advanced artificial intelligence, the app aims to support informed decision-making and better diabetes management in everyday life.

The addition of the new sites marks an important milestone for the study, enabling more people to participate and contribute to the evaluation of the MELISSA app in real-world settings across Europe.

You can find more information about the clinical study and contact details for participating sites here.